Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 31 of 47 for:    somatostatin analogues | Neuroendocrine Tumors

Open Label Study to Analyze the Effect of Telotristat Ethyl on Weight Regulation/Gain

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04034745
Recruitment Status : Not yet recruiting
First Posted : July 26, 2019
Last Update Posted : July 26, 2019
Sponsor:
Collaborator:
Lexicon Pharmaceuticals
Information provided by (Responsible Party):
Andrew Hendifar, MD, Cedars-Sinai Medical Center

Brief Summary:
This single arm study will evaluate whether Xermelo (telotristat ethyl) associated weight gain is affects lean body mass, dietary intake, and physical and cognitive functioning among neuroendocrine tumor (NET) patients with a history of carcinoid syndrome.

Condition or disease Intervention/treatment
Pancreatic Cancer Neuroendocrine Tumors Cachexia; Cancer Drug: telotristat ethyl

Detailed Description:
The purpose of this study is to examine the mechanisms of weight gain associated with the drug telotristat ethyl (Xermelo) among patients with a neuroendocrine tumor (NET) with history of carcinoid syndrome. We want to know if taking Xermelo affects patients' lean body mass, quality of life, dietary intake, and physical and cognitive functioning during treatment. A better understanding of the mechanisms of weight gain from Xermelo may allow us to determine whether this drug may be beneficial for treating carcinoid syndrome, cachexia, or weight loss seen in other diseases.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 30 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: IIT2018-26 -Hendifar-NETCx: A Phase IV Descriptive, Multicenter, Single-arm, Open Label Study to Analyze the Effect of Telotristat Ethyl on Weight Regulation/Gain
Estimated Study Start Date : August 2019
Estimated Primary Completion Date : August 2022
Estimated Study Completion Date : August 2023


Group/Cohort Intervention/treatment
Standard of Care telotristat ethyl (Xermelo) Treatment
Treatment of telotristat ethyl (Xermelo) with DXA scans and bionutritional assessments (24-hour food recall and taste/smell alteration) conducted 3x during telotristat ethyl treatment.
Drug: telotristat ethyl
250 mg tablets of Xermelo (telotristat ethyl) is administered orally 3x daily in combination with somatostatin analogs (SSAs) for approximately 84 days as per standard of care
Other Name: Xermelo




Primary Outcome Measures :
  1. Mean change in lean body mass (measured using DXA Scan) from baseline and after 13 weeks of treatment. [ Time Frame: From baseline to 13 weeks after treatment ]

Secondary Outcome Measures :
  1. Mean change in patient reported outcomes using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) from baseline up to 3 years post treatment. [ Time Frame: From baseline to 3 years post treatment ]
    The summary score (SS) is a mean of 13 QLQ-C30 subscale scores, ranging from 0 to 100, with a higher SS rating reflecting a better health status.

  2. Mean change in patient reported outcomes using the Montreal Cognitive Assessment (MOCA) test from baseline up to 3 years post treatment. [ Time Frame: From baseline to 3 years post treatment ]
    MOCA scores range between 0 and 30, with higher scores indicating higher cognitive function.

  3. Mean change in patient reported outcomes using a stool survey measured from baseline and after 13 weeks of treatment. [ Time Frame: From baseline to 13 weeks post-treatment. ]
    The stool survey is a non-validated descriptive measure of gastrointestinal symptoms by taking the mean score on a scale of 0 - 10, where 0 indicates no symptoms and higher scores denote a worsening of symptoms.

  4. Mean change in calories consumed using a 24-hour food diary from baseline and after 13 weeks of treatment. [ Time Frame: From baseline to 13 weeks post-treatment ]
  5. Mean change in daily activity levels (steps) as measured using a wrist-worn fitness tracker (e.g., Fitbit) from baseline and for the duration of the 13 weeks of treatment. [ Time Frame: From baseline to 13 weeks post-treatment ]
  6. Mean change in daily activity levels [stairs (floors) climbed] as measured using a wrist-worn fitness tracker (e.g., Fitbit) from baseline and for the duration of the 13 weeks of treatment. [ Time Frame: From baseline to 13 weeks post-treatment ]
  7. Mean change in daily activity levels (sleep duration) as measured using a wrist-worn fitness tracker (e.g., Fitbit) from baseline and for the duration of the 13 weeks of treatment. [ Time Frame: From baseline to 13 weeks post-treatment ]
  8. Mean change in daily activity levels (heart rate) as measured using a wrist-worn fitness tracker (e.g., Fitbit) from baseline and for the duration of the 13 weeks of treatment. [ Time Frame: From baseline to 13 weeks post-treatment ]
  9. Mean change in daily activity levels (active minutes) as measured using a wrist-worn fitness tracker (e.g., Fitbit) from baseline and for the duration of the 13 weeks of treatment. [ Time Frame: From baseline to 13 weeks post-treatment ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients will be recruited from Cedars-Sinai Medical Center
Criteria

Inclusion Criteria:

  • Age ≥ 18 years.
  • Histopathologically confirmed diagnosis of a metastatic NET.
  • Documented history of carcinoid syndrome.
  • Currently receiving treatment with long-acting SSAs with a plan to initiate therapy with telotristat-ethyl as per standard of care.
  • ECOG performance status 0-1 and/or Karnofsky >60%.
  • Greater than or equal to 3 month life expectancy.
  • Ability to understand and the willingness to sign a written informed consent.

Exclusion Criteria:

  • Patients experiencing more than 12 watery BMs per day associated with volume contraction, dehydration, or hypotension, or showing evidence of enteric infection.
  • History of short bowel syndrome.
  • Clinically important baseline elevation in liver function tests.
  • Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
  • Malignant ascites requiring paracenteses.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Bowel obstruction, partial, or total.
  • Pregnancy
  • Patients with unresolved grade 3/4 adverse effects of prior therapy at time of enrollment, other than diarrhea

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04034745


Contacts
Layout table for location contacts
Contact: Karen Kearns 310-967-0692 Karen.Kearns@cshs.org
Contact: Veronica Placencio, PhD 310-423-1434 Veronica.Placencio@cshs.org

Sponsors and Collaborators
Andrew Hendifar, MD
Lexicon Pharmaceuticals
Investigators
Layout table for investigator information
Principal Investigator: Andrew Hendifar, MD, MPH Cedars-Sinai Medical Center

Layout table for additonal information
Responsible Party: Andrew Hendifar, MD, Assistant Professor of Medicine, Cedars-Sinai Medical Center
ClinicalTrials.gov Identifier: NCT04034745     History of Changes
Other Study ID Numbers: IIT2018-26 -Hendifar-NETCx
First Posted: July 26, 2019    Key Record Dates
Last Update Posted: July 26, 2019
Last Verified: July 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroendocrine Tumors
Neoplasms
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Cachexia
Emaciation
Weight Loss
Body Weight Changes
Body Weight
Signs and Symptoms